Efficacy and safety of canakinumab in patients with adult-onset Still’s disease: Results from an open-label phase III study in Japan
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag026 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Tatsuya Atsumi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Still's Disease, Adult-Onset, Antibodies, Monoclonal, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the efficacy and safety of canakinumab 4 mg/kg every 4 weeks administered subcutaneously in Japanese adult-onset Still’s disease patients.
Methods
Fourteen participants were included in this open-label, single-arm, active-treatment study. The primary endpoint was the adapted ACR30 response, with a predefined 95% CI lower limit requirement of 40% at Week 8. Secondary endpoints included glucocorticoid tapering from Weeks 8 to 28; adapted ACR30/50/70/90/100 responses over time; and the systemic feature score over time.
Results
The primary endpoint was not met [6/11 patients (54.5%); 95% CI: 20.6–88.5; one-sided P = 0.249]. From Weeks 8 to 28, 6/11 patients (54.5%) successfully tapered oral glucocorticoids. At Week 28, among the 11 patients assessed, 70% achieved adapted ACR30 and adapted ACR50, 60% achieved adapted ACR70 and adapted ACR90, and 40% achieved adapted ACR100. At Week 28, the mean (SD) change from baseline in the systemic feature score was −4.3 (2.06). All 14 patients had at least one treatment-emergent adverse event. Six participants (42.9%) had serious adverse events. Three patients had serious infections; all were considered treatment-related and all recovered.
Conclusion
Although the primary endpoint was not met, the Week 28 analysis showed that canakinumab treatment led to improvements in various efficacy outcome measures in Japanese patients with adult-onset Still’s disease, with no unexpected safety signals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University, Sapporo, Japan.
- Department of Stem Cell and Immune Regulation, Yokohama City University, Yokohama, Japan.
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
- Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Department of Nephrology and Rheumatology, Kanazawa University, Kanazawa, Japan.
ORCID-Profile: Yohei Kirino, Yuko Kaneko
Zitieren
APA
Atsumi, T., Kirino, Y., Kishimoto, M., Furuta, S., Kaneko, Y., Iwata, Y., Fujio, K., Mimura, T., Kawaai, S., Wakabayashi, R., Seko, N., Hongo, W., Patekar, M., & Kawakami, A. (2026). Efficacy and safety of canakinumab in patients with adult-onset Still’s disease: Results from an open-label phase III study in Japan. Modern Rheumatology. https://doi.org/10.1093/mr/roag026
Vancouver
Atsumi T, Kirino Y, Kishimoto M, Furuta S, Kaneko Y, Iwata Y, et al. Efficacy and safety of canakinumab in patients with adult-onset Still’s disease: Results from an open-label phase III study in Japan. Modern Rheumatology. 2026. doi:10.1093/mr/roag026
BibTeX
@article{Atsumi2026,
author = {Atsumi, Tatsuya and Kirino, Yohei and Kishimoto, Mitsumasa and Furuta, Shunsuke and Kaneko, Yuko and Iwata, Yasunori and Fujio, Keishi and Mimura, Toshihide and Kawaai, Satoshi and Wakabayashi, Ryota and Seko, Noriko and Hongo, Wataru and Patekar, Manmath and Kawakami, Atsushi},
title = {Efficacy and safety of canakinumab in patients with adult-onset Still’s disease: Results from an open-label phase III study in Japan},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag026}
}
EUVIMED